Innate Pharma announces its participation to major upcoming medical meetings
New data presented at the Annual Meeting of the American Society of Hematology (“ASH”)
Innate Pharma initiates collaboration with Celgene to evaluate the clinical potential of REVLIMID® combined with anti-kir antibody IPH 2101 in patients with multiple myeloma
Innate Pharma reports Phase II clinical data with IPH 1101 in oncology
Inserm Transfert and Innate Pharma enter into an innovative partnership for the development of new antibodies for the treatment of cancer and inflammatory or autoimmune diseases
Start of the first Phase II clinical trial with monoclonal antibody IPH 2101 supported by a new 2.9 million euros financing from Oséo
Innate Pharma reports positive Phase IIa clinical results for IPH 1101 (γδT cell agonist) in type C viral hepatitis
Innate Pharma reports preliminary Phase I clinical data for IPH 2101 (a novel, anti-KIR monoclonal antibody activating NK cells) at the ASCO meeting
Innate Pharma and Novo Nordisk A/S sign licensing deal
Innate Pharma announces the achievement of the first milestone in its collaboration with Novo Nordisk A/S
